Impedimed Stock Target Price
| IPD Stock | 0.05 0 2.00% |
Impedimed fundamentals help investors to digest information that contributes to Impedimed's financial success or failures. It also enables traders to predict the movement of Impedimed Stock. The fundamental analysis module provides a way to measure Impedimed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Impedimed stock.
Impedimed | Target Price |
Impedimed Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Impedimed's direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Impedimed could also be used in its relative valuation, which is a method of valuing Impedimed by comparing valuation metrics of similar companies.Impedimed is currently under evaluation in target price category among its peers.
Impedimed Fundamentals
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.92) % | ||||
| Operating Margin | (2.01) % | ||||
| Current Valuation | 79.71 M | ||||
| Shares Outstanding | 2.02 B | ||||
| Shares Owned By Insiders | 9.13 % | ||||
| Shares Owned By Institutions | 16.29 % | ||||
| Price To Book | 2.53 X | ||||
| Price To Sales | 10.00 X | ||||
| Revenue | 10.32 M | ||||
| Gross Profit | 9.8 M | ||||
| EBITDA | (22.05 M) | ||||
| Net Income | (19.79 M) | ||||
| Cash And Equivalents | 13.55 M | ||||
| Total Debt | 1.14 M | ||||
| Book Value Per Share | 0.02 X | ||||
| Cash Flow From Operations | (17.79 M) | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 0.15 | ||||
| Number Of Employees | 83 | ||||
| Beta | 2.87 | ||||
| Market Capitalization | 103.2 M | ||||
| Total Asset | 46.99 M | ||||
| Retained Earnings | (330.95 M) | ||||
| Working Capital | 24.8 M | ||||
| Net Asset | 46.99 M |
About Impedimed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Impedimed's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Impedimed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Impedimed based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Impedimed Stock Analysis
When running Impedimed's price analysis, check to measure Impedimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Impedimed is operating at the current time. Most of Impedimed's value examination focuses on studying past and present price action to predict the probability of Impedimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Impedimed's price. Additionally, you may evaluate how the addition of Impedimed to your portfolios can decrease your overall portfolio volatility.